Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
ALHAMBRA, Calif. - Astrana Health, Inc. (NASDAQ: ASTH), a healthcare company leveraging AI technology to enhance value-based care delivery, announced the appointment of Sherry McBride as Chief Operating Officer, effective Monday. McBride’s role will focus on operational integration and execution within the company’s Management Services Organization, contributing to the growth of Astrana’s care delivery platform. The appointment comes as the company, currently valued at $1.2 billion, demonstrates strong revenue growth of nearly 55% over the last twelve months.
With over 18 years of experience in value-based healthcare operations, McBride’s expertise lies in managing Medicare Advantage global risk businesses and building profitable provider group businesses. Her most recent tenure was as COO of Providence Health Network. The move is seen as a strategic step for Astrana as it aims to strengthen its operations and care model integration during a period of expansion. According to InvestingPro data, the company has maintained profitability with a healthy current ratio of 1.7 and strong revenue of $2.25 billion in the last twelve months.
President and CEO Brandon Sim expressed enthusiasm for McBride’s appointment, highlighting her deep experience and the potential impact on the company’s mission to deliver consistent, high-quality patient outcomes. Sim also noted the addition of other key executives, including Georgie Sam as Chief Data and Analytics Officer, Glenn Sobotka as Chief Accounting Officer, and the promotion of Rita Pew to Chief People Officer. These appointments are intended to enhance Astrana’s capabilities in operations, data, finance, and talent management.
Astrana Health aims to deliver patient-centered care through its AI-powered technology platform and provider networks. Currently, the company supports over 12,000 providers and serves more than one million patients in value-based care arrangements. The leadership expansion is part of Astrana’s strategy to manage healthcare for over 1.7 million patients nationwide, driving better outcomes for patients and providers alike. While the stock has faced recent pressure, trading near its 52-week low, InvestingPro analysis suggests the company is currently undervalued, with analysts maintaining a strong buy consensus and projecting continued net income growth. For deeper insights into Astrana’s financial health and growth potential, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
This information is based on a press release statement from Astrana Health, Inc.
In other recent news, Astrana Health reported its Q1 2025 earnings, which fell short of expectations, with an earnings per share (EPS) of $0.14 compared to the forecasted $0.30. The company’s revenue also missed projections, coming in at $620.4 million against an expected $628.11 million. Despite this earnings miss, Astrana Health achieved a significant 53% year-over-year revenue increase. The company’s strategic expansions into Nevada and Texas are part of its growth strategy, although challenges in maintaining EPS growth have been noted. Analysts have expressed concerns about potential profitability issues due to the earnings miss. Astrana Health’s ongoing integration of recent acquisitions, including CHS, is a focus, with expectations of reaching breakeven profitability in 2025. The company anticipates closing its acquisition of Prospect Health in the summer, which is expected to expand its provider network significantly. Looking forward, Astrana Health projects Q2 2025 revenue between $615 million and $665 million, with adjusted EBITDA ranging from $45 million to $50 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.